Contact information
John Geddes
MD FRCPsych
WA Handley Professor of Psychiatry
Mood Disorders, Bipolar Disorder, Clinical Trials
John has led several trials and research syntheses which have had major influence on clinical practice internationally.
John is a member of the Academia Europaea, an Honorary Fellow of the American College of Psychiatrists and was awarded the European College of Neuropsychopharmacology (ECNP) Neuropsychopharmacology Award in 2016 in recognition of his ground-breaking work on the psychopharmacology of bipolar disorder. He was awarded an honorary doctorate by Aristotle University of Thessaloniki in 2018.
His current research focuses on the development and evaluation of treatments for people with mood disorders. John has developed new approaches to self management and monitoring, and conducted key clinical trials as well as influential research syntheses.
Recent publications
-
Reducing inequalities through greater diversity in clinical trials – As important for medical devices as for drugs and therapeutics
Journal article
Roope LSJ. et al, (2025), Contemporary Clinical Trials Communications, 45
-
Effect of lithium on circadian activity level and flexibility in patients with bipolar disorder: results from the Oxford Lithium Trial.
Journal article
Xu N. et al, (2025), EBioMedicine, 115
-
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK.
Journal article
Cleare AJ. et al, (2025), Lancet Psychiatry, 12, 276 - 288
-
Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment.
Journal article
Scholl J. et al, (2025), Mol Psychiatry
-
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study).
Journal article
McAllister-Williams RH. et al, (2025), J Psychopharmacol